Cognitive slowing in multiple sclerosis is strongly associated with brain                 volume reduction

Lazeron, R.H.C.; Sonneville, Leo de; Scheltens, Philip; Polman, Chris H.; Barkhof, Frederik

doi:10.1177/1352458506070924

Cited by 55 publications

(39 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Associations between MRI disease measures and performance on individual cognitive tests have been reported previously [6,18,31], including correlations between lesion volume and measures of attention and information processing. Impairment of different cognitive functions may, therefore, reflect specific brain pathology.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 66%

“…In addition, several studies have found an association between cognitive function and disease course [15][16][17]. Moderate-to-strong correlations have been reported between cognitive impairment and magnetic resonance imaging (MRI) disease measures, including T1 and T2 lesion volumes [6,17], brain volume [18], and cortical atrophy [19].…”

Section: Introductionmentioning

confidence: 99%

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Brain volume reduction, assessed by MRI, has been shown to correlate better than lesion load with speed of cognitive processing; suggesting that pathology beyond focal lesions may be important in MS (39). The notion of more diffuse pathological changes taking place in the normal appearing GM and WM was confirmed by the observation that neuronal loss occurs in the medial dorsal nucleus of the thalamus in the absence of demyelinating plaques (14).…”

Section: Discussionmentioning

confidence: 99%

Substantial Archaeocortical Atrophy and Neuronal Loss in Multiple Sclerosis

Papadopoulos¹,

Dukes²,

Patel³

et al. 2009

Brain Pathology

182

198

View full text Add to dashboard Cite

Recent studies have revealed extensive neocortical pathology in multiple sclerosis (MS). The hippocampus is a unique archaeocortical structure understudied in MS. It plays a central role in episodic and anterograde memory-the most frequently impaired cognitive modalities in MS. This histopathological study aimed to investigate inflammatory demyelination and neurodegenerative changes in the MS archaeocortex. A detailed quantitative analysis was performed on hippocampal autopsy tissue from 45 progressive MS cases and seven controls. Forty-one lesions were identified in 28 of the 45 hippocampal MS-blocks examined, with percentage area of demyelination averaging 30.4%. The majority of lesions were chronic and subpially or subependymally located. Compared to controls, neuronal numbers were decreased by 27% in CA1 and 29.7% in CA3-2. Furthermore, the size of neurones was decreased by 17.4% in CA1. There was evidence of gross hippocampal atrophy with a 22.3% reduction in the average cross-sectional area, which correlated with neuronal loss. Our study provides evidence of substantial archaeocortical pathology largely resembling patterns seen in the neocortex and suggests that hippocampal involvement could contribute to memory impairments often seen in MS.

show abstract

“…Using a test that probes various domains of attention, Lazeron et al [63] measured the processing speed and performance accuracy of 32 patients with different subtypes of MS (11 RR-, 13 SP-and 8 PPMS). They revealed that a greater reduction in brain volume was significantly associated with a slower processing speed but not with reduced performance accuracy in MS, as the latter remained stable [63].…”

Section: Correlation Between Atrophy and Cognitionmentioning

confidence: 99%

Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review

et al. 2009

View full text Add to dashboard Cite

Multiple sclerosis is known to be an inflammatory demyelinating disease characterized mainly by multifocal areas of white matter lesions. Recently, cortical lesions and brain atrophy have emerged as new pathological markers of disease progression. Brain tissue loss can now be easily and reproducibly detected and quantified by MRI, which has led to an increasing amount of research correlating brain tissue loss with other MRI markers, such as white matter lesions, and to clinical disabilities (motor or cognitive), in order to assess its clinical relevance. In this review, we summarize the different MRI-based methods used to quantify whole and regional brain atrophy, and discuss the relevance of brain atrophy in MS through its relationship with characteristic brain lesions, disability and cognition. Lastly, we emphasize the role of brain atrophy in different phenotypes of MS. According to this review of the current literature, the grey matter (GM) atrophy is now well-established in MS and has been found to be strongly associated with clinical and cognitive deterioration. This GM volume loss is characterized by a focal atrophy in the deep grey nuclei but also by diffuse cortical atrophy. Phenotypic variation can be associated with different degrees and regional location of brain atrophy but more investigations are necessary to specify the discrepancies against brain atrophy between the different forms of the disease.

show abstract

Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction

Cited by 55 publications

References 38 publications

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

Substantial Archaeocortical Atrophy and Neuronal Loss in Multiple Sclerosis

Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review

Contact Info

Product

Resources

About